BACKGROUND: There is little consensus on the most efficacious vehicle substance for vitamin D supplements. Fat malabsorption may impede the ability of patients with cystic fibrosis (CF) to absorb vitamin D in an oil vehicle. We hypothesized that vitamin D contained in a powder vehicle would be absorbed more efficiently than vitamin D contained in an oil vehicle in patients with CF. METHODS: In this double-blind, randomized controlled trial, hospitalized adults with CF were given a one-time bolus dose of 100,000 IU of cholecalciferol (D3) in a powder-based or oil-based vehicle. Serum D3, 25-hydroxyvitamin D, and parathyroid hormone concentrations were analyzed at 0, 12, 24, and 48 hours posttreatment. The area under the curve for serum D3 and the 12-hour time point were also assessed as indicators of D3 absorption. RESULTS: This trial was completed by 15 patients with CF. The median (interquartile range) age, body mass index, and forced expiratory volume in 1 second were 23.7 (19.9-33.2) years, 19.9 (18.6-22.6) kg/m2, and 63% (37%-80%), respectively. The increase in serum D3 and the area under the curve was greater in the powder group ( P = .002 and P = .036, respectively). Serum D3 was higher at 12 hours in the powder group compared with the oil group ( P = .002), although levels were similar between groups by 48 hours. CONCLUSIONS: In adults with CF, cholecalciferol is more efficiently absorbed in a powder compared with an oil vehicle. Physicians should consider prescribing vitamin D in a powder vehicle in patients with CF to improve the absorption of vitamin D from supplements.
RCT Entities:
BACKGROUND: There is little consensus on the most efficacious vehicle substance for vitamin D supplements. Fat malabsorption may impede the ability of patients with cystic fibrosis (CF) to absorb vitamin D in an oil vehicle. We hypothesized that vitamin D contained in a powder vehicle would be absorbed more efficiently than vitamin D contained in an oil vehicle in patients with CF. METHODS: In this double-blind, randomized controlled trial, hospitalized adults with CF were given a one-time bolus dose of 100,000 IU of cholecalciferol (D3) in a powder-based or oil-based vehicle. Serum D3, 25-hydroxyvitamin D, and parathyroid hormone concentrations were analyzed at 0, 12, 24, and 48 hours posttreatment. The area under the curve for serum D3 and the 12-hour time point were also assessed as indicators of D3 absorption. RESULTS: This trial was completed by 15 patients with CF. The median (interquartile range) age, body mass index, and forced expiratory volume in 1 second were 23.7 (19.9-33.2) years, 19.9 (18.6-22.6) kg/m2, and 63% (37%-80%), respectively. The increase in serum D3 and the area under the curve was greater in the powder group ( P = .002 and P = .036, respectively). Serum D3 was higher at 12 hours in the powder group compared with the oil group ( P = .002), although levels were similar between groups by 48 hours. CONCLUSIONS: In adults with CF, cholecalciferol is more efficiently absorbed in a powder compared with an oil vehicle. Physicians should consider prescribing vitamin D in a powder vehicle in patients with CF to improve the absorption of vitamin D from supplements.
Authors: Michael P Boyle; Michelle L Noschese; Sharon L Watts; Marsha E Davis; Shane E Stenner; Noah Lechtzin Journal: Am J Respir Crit Care Med Date: 2005-04-28 Impact factor: 21.405
Authors: Natasha B Khazai; Suzanne E Judd; Leo Jeng; Linda L Wolfenden; Arlene Stecenko; Thomas R Ziegler; Vin Tangpricha Journal: J Clin Endocrinol Metab Date: 2009-03-31 Impact factor: 5.958
Authors: F A Farraye; H Nimitphong; A Stucchi; K Dendrinos; A B Boulanger; A Vijjeswarapu; A Tanennbaum; R Biancuzzo; T C Chen; M F Holick Journal: Inflamm Bowel Dis Date: 2011-01-06 Impact factor: 5.325
Authors: V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Moon Jeong Lee; Jessica A Alvarez; Ellen M Smith; David W Killilea; James F Chmiel; Patricia M Joseph; Ruth E Grossmann; Amit Gaggar; Thomas R Ziegler; Vin Tangpricha Journal: Nutr Clin Pract Date: 2015-06-15 Impact factor: 3.080
Authors: Carol L Wagner; Judy R Shary; Paul J Nietert; Amy E Wahlquist; Myla D Ebeling; Bruce W Hollis Journal: Nutrients Date: 2019-05-07 Impact factor: 5.717